MNMD
NASDAQMind Medicine (MindMed) Inc.
SectorHealth CareIndustry Medicinal Chemicals and Botanical Products
Price$15.01+3.21 (+27.16%)
2025-10-102026-01-14
News · 26 weeks70%
2025-12-072026-05-31
Mix090d
No activity.
Latest news
25 items- SECMind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
- INSIDERChief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
- INSIDERChief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
- INSIDERChief Medical Officer Karlin Daniel sold $73,623 worth of shares (5,600 units at $13.15), decreasing direct ownership by 1% to 425,025 units (SEC Form 4)4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
- SECSEC Form 144 filed by Mind Medicine (MindMed) Inc.144 - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
- PRMindMed to Present at the 44th Annual J.P. Morgan Healthcare ConferenceMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that Rob Barrow, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT. "It is a privilege to participate in the J.P. Morgan Healthcare Conference as we continue to share the progress MindMed is making to forge a new era of psychiatry," said Rob Barrow, Chief Executive Officer. "The conference provides a meaningful opportunity to engage with the investment community as we prepare for a de
- PRMindMed Announces New Employee Inducement GrantMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 31,500 common shares of the Company (the "Options") with an effective grant date of December 15, 2025. The Options have an exercise price equal to the closing price of MindMed's common shares on the date of the grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantia
- PRMindMed Announces New Employee Inducement GrantsMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 182,100 common shares of the Company (the "Options") with effective grant dates of November 17, 2025, November 24, 2025 and December 1, 2025, depending on the applicable employee's respective start date. The Options have an exercise price equal to the closing price of MindMed's common shares on the date of the respective grant, and will vest over a four-year peri
- SECSEC Form 10-Q filed by Mind Medicine (MindMed) Inc.10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
- SECMind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
- PRMindMed Reports Q3 2025 Financial Results and Business Updates-- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)-- --Anticipated topline data readout from first Phase 3 study of MM120 ODT in MDD (Emerge) accelerated to mid-2026, aligning with the anticipated initiation of second Phase 3 study in MDD (Ascend)-- --MM120 Phase 2b GAD Study published in the Journal of the American Medical Association (JAMA)-- --Continued advancement of pipeline with planned Phase 2a study initiation of MM402 in Autism Spectrum Disorder (ASD) in 4Q 2025-- --Cash, cash equivalents and marketable securities totaled $209.1 million as of September 30, 2025; co
- PRMindMed to Participate in Upcoming Investor ConferencesMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Stifel 2025 Healthcare Conference Format: Presentation Date and Time: Wednesday, November 12, 2025 at 1:20 PM ET Location: New York, NY Webcast Link: Stifel 2025 Healthcare Conference Jefferies Global Healthcare Conference in London Format: Presentation Date and Time: Tuesday, November 18, 2025 at 12:00 PM GMT Location: London, UK Webcast Link: Jefferies Global He
- PRMindMed Announces New Employee Inducement GrantMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 90,750 common shares of the Company (the "Options") with an effective grant date of November 3, 2025. The Options have an exercise price equal to the closing price of MindMed's common shares on the date of the grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substanti
- PRMind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing of its previously announced underwritten public offering of 21,131,250 common shares, without par value, which includes the exercise in full by the underwriters of their option to purchase an additional 2,756,250 common shares, at a public offering price of $12.25 per common share. All of the shares were offered by MindMed. The gross proceeds from this offering were approximately $259 million, before deducting underwriting discounts and commissions and offering expenses payabl
- SECMind Medicine (MindMed) Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
- SECSEC Form 424B5 filed by Mind Medicine (MindMed) Inc.424B5 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
- PRMindMed to Report Q3 2025 Financial Results on November 6, 2025Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, November 6, 2025 to report financial results for the third quarter ended September 30, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after
- PRMind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public OfferingMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 18,375,000 common shares, without par value, at a public offering price of $12.25 per common share. The gross proceeds to MindMed from the offering, before deducting underwriting discounts, commissions, and other offering-related expenses, are expected to be approximately $225 million. In addition, MindMed has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,756,250 common shares at the public of
- SECMind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
- SECSEC Form 424B5 filed by Mind Medicine (MindMed) Inc.424B5 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
- PRMind Medicine (MindMed) Inc. Announces Proposed Public OfferingMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. In addition, MindMed intends to grant the underwriters an option for a period of 30 days to purchase additional common shares at the public offering price, less underwriting discounts and commissions. All of the common shares and pre-funded warrants are being offered by MindMed. MindMed intends to use
- PRMindMed Announces New Employee Inducement GrantMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to one newly hired non-executive employee consisting of an option to purchase 28,000 common shares of the Company (the "Option") with an effective grant date of October 14, 2025. The Option has an exercise price equal to the closing price of MindMed's common shares on the date of the grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly i
- ANALYSTNeedham initiated coverage on MindMed with a new price targetNeedham initiated coverage of MindMed with a rating of Buy and set a new price target of $28.00
- INSIDERChief Legal Officer Sullivan Mark sold $110,186 worth of shares (11,278 units at $9.77), decreasing direct ownership by 4% to 293,852 units (SEC Form 4)4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
- INSIDERChief Executive Officer Barrow Robert sold $252,037 worth of shares (25,797 units at $9.77), decreasing direct ownership by 3% to 804,268 units (SEC Form 4)4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
MNMD FAQ
6 questionsWhat does Mind Medicine (MindMed) Inc. do?
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.Where does MNMD stock trade?
Mind Medicine (MindMed) Inc. (MNMD) is listed on NASDAQ.What sector and industry is MNMD in?
Mind Medicine (MindMed) Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.What are analysts saying about MNMD?
Mind Medicine (MindMed) Inc. has had 8 recent analyst actions on file. The most recent action was from Needham: Buy with a $2800.00 price target on 2025-10-13. Recent price targets range from $2000.00 to $3600.00.What companies are similar to MNMD?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), RGC (Regencell Bioscience Holdings Limited), RLX (RLX Technology Inc.). Compare MNMD side-by-side with any of them on Quantisnow.How can I track MNMD on Quantisnow?
Quantisnow aggregates Mind Medicine (MindMed) Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNMD to receive live email and push alerts on every new disclosure.